title: Inactivation of glyceraldehyde-3-phosphate dehydrogenase by fumarate in diabetes: formation of S-(2-succinyl)cysteine, a novel chemical modification of protein and possible biomarker of mitochondrial stress.
abstract: OBJECTIVE
  (2-succinyl)cysteine (2SC) is formed by a Michael addition reaction of the Krebs cycle intermediate, fumarate, with cysteine residues in protein. We investigated the role of fumarate in chemical modification and inhibition of the sulfhydryl enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in vitro and in tissues of diabetic rats.
  
  
  METHODS
  GAPDH was incubated with fumarate in PBS to assess effects of fumarate on enzyme activity in vitro. Sites of 2SC formation were determined by analysis of tryptic peptides by high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry. 2SC and fumarate in gastrocnemius muscle of control and streptozotocin-induced diabetic rats were measured by liquid chromatography/tandem mass spectrometry and by gas chromatography/mass spectrometry, respectively. GAPDH was isolated from muscle by immunoprecipitation, and sites of modification of GAPDH were determined by mass spectrometry analysis.
  
  
  RESULTS
  2SC was found, both in vitro and in vivo, about equally at active-site Cys-149 and nucleophilic Cys-244. Inactivation of GAPDH by fumarate in vitro correlated with formation of 2SC. In diabetic compared with control rats, fumarate and 2SC concentration increased approximately fivefold, accompanied by an approximately 25% decrease in GAPDH specific activity. The fractional modification of GAPDH by 2SC was significantly increased in diabetic versus control animals, consistent with the decreased specific activity of GAPDH in muscle of diabetic animals.
  
  
  CONCLUSIONS
  Fumarate contributes to inactivation of GAPDH in diabetes. 2SC may be a useful biomarker of mitochondrial stress in diabetes. Modification of GAPDH and other enzymes and proteins by fumarate may contribute to the metabolic changes underlying the development of diabetes complications.
authors.affiliation: Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Blatnik
authors.forename: Norma
authors.initials: N
authors.lastname: Frizzell
authors.forename: Suzanne R
authors.initials: SR
authors.lastname: Thorpe
authors.forename: John W
authors.initials: JW
authors.lastname: Baynes
mesh_terms: D000818:Animals; D002853:Chromatography, Liquid; D003545:Cysteine / Q000031:analogs & derivatives* / Q000032:analysis / Q000302:isolation & purification; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology*; D005650:Fumarates / Q000494:pharmacology*; D008401:Gas Chromatography-Mass Spectrometry; D024601:Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D007700:Kinetics; D013058:Mass Spectrometry; D008928:Mitochondria / Q000201:enzymology / Q000502:physiology*; D018482:Muscle, Skeletal / Q000201:enzymology; D010446:Peptide Fragments / Q000302:isolation & purification; D051381:Rats
chemical_list: D005650:Fumarates; D010446:Peptide Fragments; C511650:S-(2-succinyl)cysteine; D024601:Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); D003545:Cysteine